AI English summary of an SEC filing — figures as filed
Kenvue KVUEKenvue said net sales for the 9 months ended September 29, 2024 were $11.8 billion, flat with the prior-year period, and rose $15 million (0.1%). Excluding the impact of foreign currency, organic growth was $168 million (1.4%).
Key points
AI summaryKenvue said net sales for the 9 months ended September 29, 2024 were $11.8 billion, flat with the prior-year period, and rose $15 million (0.1%). Excluding the impact of foreign currency, organic growth was $168 million (1.4%).
The company said gross profit margin expanded 240 basis points to 58.4% from 56.0% in the 9 months, and selling, general and administrative expenses as a share of net sales rose 200 basis points to 40.7% from 38.7%. It cited supply chain optimization benefits and higher brand marketing expenses as factors.
The company said it recognized impairment charges of $578 million in the 9 months, including a non-cash charge related to the Dr.Ci:Labo® skin health business of $488 million ($337 million after tax). It said there were no impairment charges in the 3-month quarter.
Kenvue said operating cash flow for the 9 months was $976 million, a decrease of $1,242 million from $2,218 million in the prior-year period. As of September 29, 2024, cash and cash equivalents totaled $1,057 million, and the balance outstanding under its Commercial Paper Program was $887 million, net of a discount of $3 million.
Key figures
Quarter ended September 29, 2024
- Revenue
- $3.9B
- Operating income
- $654M
- Net income
- $383M
- EPS
- $0.20
- Gross profit
- $2.3B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Kenvue 9-month net sales $11.8 billion, organic growth 1.4%
Kenvue said net sales for the 9 months ended September 29, 2024 were $11.8 billion, flat with the prior-year period, and rose $15 million (0.1%). Excluding the impact of foreign currency, organic growth was $168 million (1.4%).
Source · Based on the MD&A text of the filing
Gross margin 58.4%, SG&A share of sales 40.7%
The company said gross profit margin expanded 240 basis points to 58.4% from 56.0% in the 9 months, and selling, general and administrative expenses as a share of net sales rose 200 basis points to 40.7% from 38.7%. It cited supply chain optimization benefits and higher brand marketing expenses as factors.
Source · Based on the MD&A text of the filing
Impairment charges $578 million including Dr.Ci:Labo
The company said it recognized impairment charges of $578 million in the 9 months, including a non-cash charge related to the Dr.Ci:Labo® skin health business of $488 million ($337 million after tax). It said there were no impairment charges in the 3-month quarter.
Source · Based on the MD&A text of the filing
Operating cash flow $976 million, cash $1,057 million
Kenvue said operating cash flow for the 9 months was $976 million, a decrease of $1,242 million from $2,218 million in the prior-year period. As of September 29, 2024, cash and cash equivalents totaled $1,057 million, and the balance outstanding under its Commercial Paper Program was $887 million, net of a discount of $3 million.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
You can verify the report’s figures and statements in the original filing on SEC EDGAR.